Jane Street
JNCE

Jane Street’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Jane Street’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-126,048
Closed -$233K – 9987
2023
Q1 		$233K Buy
126,048
+108,127
+603% +$134K ﹤0.01% 7598
2022
Q4 		$19.9K Buy
+17,921
New +$25.5K ﹤0.01% 8613

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Jane Street's JNCE Position: Q2 2023 in Review

Jane Street sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 126,048 shares — an estimated $233K sold.

Jane Street first reported a position in JNCE in Q4 2022 and held it in 2 quarters. The position peaked at $233K in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • Jane Street reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Jane Street sold 126,048 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $233K.
  • Jane Street first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Jane Street's Jounce Therapeutics, Inc. Common Stock position peaked at $233K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Jane Street's 13F filing for Q2 2023, filed 14 Aug 2023.